山东大学学报 (医学版) ›› 2023, Vol. 61 ›› Issue (9): 69-78.doi: 10.6040/j.issn.1671-7554.0.2023.0150
宋兆录1,董正璇2,彭传真1,黄彩娜2,胡克清1,黄永胜3,阎磊3
SONG Zhaolu1, DONG Zhengxuan2, PENG Chuanzhen1, HUANG Caina2, HU Keqing1, HUANG Yongsheng3, YAN Lei3
摘要: 目的 探讨肾透明细胞癌(ccRCC)中与患者生存预后相关的RNA编辑位点。 方法 下载癌症基因组图谱(TCGA)中RNA编辑位点的表达数据,使用最小绝对收缩和选择算子(LASSO)及Cox回归筛选出与ccRCC预后密切关联的RNA编辑位点。根据多因素Cox结果计算患者的风险评分后构建预后模型和列线图,进一步采用接受者操作特征(ROC)曲线评估预后模型和列线图的准确性,并进行相关的功能学分析。 结果 共筛选出25个与ccRCC预后相关的RNA编辑位点。根据风险评分的中位值将患者分为高风险组(n=222)与低风险组(n=226)。Kaplan-Meier生存分析结果显示,高风险组患者的总生存时间与疾病无进展生存时间均低于低风险组(P<0.001)。预后模型和列线图预测患者1、3、5年生存的曲线下面积(AUC)值分别为0.801、0.824和0.806、0.858,0.833和0.821。风险分组之间具备不同的生物学功能及药物敏感性。 结论 通过公共数据库筛选出的25个RNA编辑位点有望会成为ccRCC患者新的预后标记物。
中图分类号:
[1] Linehan WM, Schmidt LS, Crooks DR, et al. The metabolic basis of kidney Cancer [J]. Cancer Discov, 2019, 9(8): 1006-1021. [2] 中国医疗保健国际交流促进会泌尿健康促进分会. 肾癌基因检测中国专家共识(2021版)[J]. 现代泌尿外科杂志, 2022, 27(3): 192-200. China Association for the Promotion of International Exchange of Medical Care Urinary Health Promotion Branch. Chinese expert consensus on kidney cancer gene testing(2021 version)[J]. Journal of Modern Urology, 2022, 27(3): 192-200. [3] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020 [J]. CA Cancer J Clin, 2020, 70(1): 7-30. [4] Go H, Kang MJ, Kim PJ, et al. Development of response classifier for vascular endothelial growth factor receptor(VEGFR)-tyrosine kinase inhibitor(TKI)in metastatic renal cell carcinoma [J]. Pathol Oncol Res, 2019, 25(1): 51-58. [5] Liu J, Wang F, Zhang Y, et al. ADAR1-Mediated RNA editing and its role in cancer [J]. Front Cell Dev Biol, 2022, 10: 956649. doi: 10.3389/fcell.2022.956649. [6] Kurkowiak M, Arcimowicz L, Chrusciel E, et al. The effects of RNA editing in cancer tissue at different stages in carcinogenesis [J]. RNA Biol, 2021, 18(11): 1524-1539. [7] Park E, Jiang Y, Hao L, et al. Genetic variation and microRNA targeting of A-to-I RNA editing fine tune human tissue transcriptomes [J]. Genome Biol, 2021, 22(1): 77. doi: 10.1186/s13059-021-02287-1. [8] Peng X, Xu X, Wang Y, et al. A-to-I RNA editing contributes to proteomic diversity in cancer [J]. Cancer Cell, 2018, 33(5): 817-828. [9] Chigaev M, Yu H, Samuels DC, et al. Genomic positional dissection of RNA editomes in tumor and normal samples [J]. Front Genet, 2019, 10: 211. doi: 10.3389/fgene.2019.00211. eCollection 2019. [10] Sun Z, Qin X, Fang J, et al. Multi-omics analysis of the expression and prognosis for FKBP gene family in renal cancer [J]. Front Oncol, 2021, 11: 697534. doi: 10.3389/fonc.2021.697534. eCollection 2021. [11] Teng PC, Liang Y, Yarmishyn AA, et al. RNA Modifications and epigenetics in modulation of lung cancer and pulmonary diseases [J]. Int J Mol Sci, 2021, 22(19):10592. doi: 10.3390/ijms221910592. [12] Song B, Shiromoto Y, Minakuchi M, et al. The role of RNA editing enzyme ADAR1 in human disease [J]. Wiley Interdiscip Rev RNA, 2022, 13(1): e1665. doi: 10.1002/wrna.1665. [13] Jiang L, Hao Y, Shao C, et al. ADAR1-mediated RNA editing links ganglioside catabolism to glioblastoma stem cell maintenance [J]. Clin Invest, 2022, 132(6): e143397. doi: 10.1172/JCI143397. [14] Nakamura K, Shigeyasu K, Okamoto K, et al. ADAR1 and AZIN1 RNA editing function as an oncogene and contributes to immortalization in endometrial cancer [J]. Gynecologic Oncology, 2022, 166(2): 326-333. [15] Shen P, Yang T, Chen Q, et al. CircNEIL3 regulatory loop promotes pancreatic ductal adenocarcinoma progression via miRNA sponging and A-to-I RNA-editing [J]. Mol Cancer, 2021, 20(1): 51. doi: 10.1186/s12943-021-01333-7. [16] Martinez HD, Jasavala RJ, Hinkson I, et al. RNA editing of androgen receptor gene transcripts in prostate cancer cells [J]. J Biol Chem, 2008, 283(44): 29938-29949. [17] Shigeyasu K, Okugawa Y, Toden S, et al. AZIN1 RNA editing confers cancer stemness and enhances oncogenic potential in colorectal cancer [J]. JCI Insight, 2018, 3(12): e99976. doi: 10.1172/jci.insight.99976. [18] Okugawa Y, Toiyama Y, Shigeyasu K, et al. Enhanced AZIN1 RNA editing and overexpression of its regulatory enzyme ADAR1 are important prognostic biomarkers in gastric cancer [J]. Transl Med, 2018, 16(1): 366. doi: 10.1186/s12967-018-1740-z. [19] Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy [J]. Cell, 2017, 168(4): 707-723. [20] 胡立勇,钟浩,房娟娟,等. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报(医学版), 2023, 61(4): 49-55. HU Liyong, ZHONG Hao, FANG Juanjuan, et al. Prognostic value of CCR gene in clear cell renal cell carcinoma based on database [J]. Journal of Shandong University(Health Sciences), 2023, 61(4): 49-55. [21] Tang SJ, Shen H, An O, et al. Cis- and trans-regulations of pre-mRNA splicing by RNA editing enzymes influence cancer development [J]. Nat Commun, 2020, 11(1): 799. [22] 杨朝华, 田宇, 安治国. RNA编辑与肿瘤[J]. 中国实验诊断学, 2004, 8(1): 89-91. YANG Zhaohua, TIAN Yu, AN Zhiguo. RNA editing and tumor [J]. Chinese Journal of Laboratory Diagnosis, 2004, 8(1): 89-91. [23] Yue Y, Liu J, He C. RNA N6-methyladenosine methylation in post-transcriptional gene expression regulation [J]. Genes Dev, 2015, 29(13): 1343-1355. [24] Chen L, Li Y, Lin CH, et al. Recoding RNA editing of AZIN1 predisposes to hepatocellular carcinoma [J]. Nat Med, 2013, 19(2): 209-216. [25] Xu LD, Öhman M. ADAR1 Editing and its role in cancer [J]. Genes(Basel), 2018, 10(1):12. doi: 10.3390/genes10010012. [26] Wu YM, Guo Y, Yu H, et al. RNA editing affects cis-regulatory elements and predicts adverse cancer survival [J]. Cancer Med, 2021, 10(17): 6114-6127. |
[1] | 胡立勇,钟浩,房娟娟,国巍,张雨露,范医东. 基于数据库分析CCR基因对肾透明细胞癌预后的预测价值[J]. 山东大学学报 (医学版), 2023, 61(4): 49-55. |
[2] | 赵凯,尹心宝,张宗亮,王振林,朱冠群,王科. 黄芪皂苷Ⅱ对肾透明细胞癌细胞生长抑制作用及机制[J]. 山东大学学报 (医学版), 2023, 61(1): 10-16. |
[3] | 张振伟,李佳,陈克明. IGF2BP2/m6A/ITGA5信号轴调控肾透明细胞增殖和迁移[J]. 山东大学学报 (医学版), 2022, 60(9): 74-84. |
[4] | 秦静,杨飞,陈谦,夏涵岱,刘延国,王秀问. 晚期驱动基因阴性、PD-L1表达阴性非鳞非小细胞肺癌一线治疗方案的网状Meta分析[J]. 山东大学学报 (医学版), 2022, 60(7): 74-82. |
[5] | 高会江,魏煜程. 微创袖式肺叶切除手术:免疫治疗时代的机遇和挑战[J]. 山东大学学报 (医学版), 2022, 60(11): 23-27. |
[6] | 于金明,颜薇薇,陈大卫. 肺癌放射免疫新实践[J]. 山东大学学报 (医学版), 2021, 59(9): 1-8. |
[7] | 邓晓惠,郭玲. 免疫治疗在胚胎反复种植失败中的应用进展[J]. 山东大学学报 (医学版), 2021, 59(8): 32-37. |
[8] | 李灿楦,陈洁. 基于生物信息学分析乙酰辅酶A酰基转移酶1在肾透明细胞癌中的表达及作用机制[J]. 山东大学学报 (医学版), 2021, 59(2): 26-33. |
[9] | 庞兆飞,柳勇,赵小刚,闫涛,陈效伟,杜贾军. 基于公共数据库构建肺腺癌肿瘤干性评分模型预测免疫治疗疗效[J]. 山东大学学报 (医学版), 2021, 59(11): 19-28. |
[10] | 栗英林,宋道庆,徐忠华. 应用生物信息学方法分析肾透明细胞癌中FKBP11的表达[J]. 山东大学学报 (医学版), 2020, 1(9): 45-51. |
[11] | 李刚,薛皓,邱伟,赵荣荣. 脑胶质瘤抑制性免疫微环境形成机制及研究进展[J]. 山东大学学报 (医学版), 2020, 1(8): 67-73. |
[12] | 罗昕,何兵,聂清生,侯震波,董军,李玉花,曾祥芹,刘伟,孔德民,曹金凤. 磁共振扩散加权成像单指数模型与扩散峰度成像模型在61例肾透明细胞癌分级中的对比[J]. 山东大学学报 (医学版), 2020, 1(7): 89-95. |
[13] | 吴德沛,陈晓晨. 淋巴瘤免疫治疗的现状及展望[J]. 山东大学学报 (医学版), 2019, 57(7): 13-20. |
[14] | 黄晓军. 细胞免疫治疗在血液系统恶性肿瘤的应用进展[J]. 山东大学学报 (医学版), 2019, 57(7): 1-5. |
[15] | 王昭. 噬血细胞性淋巴组织细胞增多症治疗的临床研究新进展[J]. 山东大学学报 (医学版), 2019, 57(7): 44-49. |
|